GSK Reaches Settlement in Illinois Zantac Lawsuit
By Najat Kantouar
GSK said it reached a confidential settlement with a plaintiff over its discontinued drug Zantac, resolving the case in an Illinois state court.
The British pharmaceutical company said Friday that it won't admit any liability in this settlement, and added that the scientific consensus didn't find any consistent or reliable evidence that ranitidine, commonly sold under the brand name Zantac, increases the risk of any cancer.
In 2020, the U.S. Food and Drug Administration requested manufacturers take Zantac off the market. The FDA concluded that the drug's ingredient, ranitidine, can form a cancer-causing contaminant, N-Nitrosodimethylamine, over time or through heat exposure.
GSK said that it would continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.
Write to Najat Kantouar at najat.kantouar@wsj.com
(END) Dow Jones Newswires
June 28, 2024 13:27 ET (17:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks